Stefan H Kappe

age ~58

from Seattle, WA

Get Report

Also known as:

Stefan Hans Kappe
Stefan S Kappe

Phone and address:: 1420 36Th Ave S, Seattle, WA 98144

Connected to:

Stefan Kappe Phones & Addresses

1420 36Th Ave S, Seattle, WA 98144
500 Wall St, Seattle, WA 98121 • 2064483552
Middletown, RI
Great River, NY
New York, NY
Bronx, NY
Canton, MI
South Bend, IN

Resumes

Stefan Kappe

view source

Us Patents

Live Genetically Attenuated Malaria Vaccine
view source
US Patent:

20050226896, Oct 13, 2005
Filed:

Mar 11, 2005
Appl. No.:

11/078200
Inventors:

Stefan Kappe - Seattle WA, US
Kai-Uwe Matuschewski - Heidelberg, DE
Ann-Kristin Mueller - Dossenheim, DE
Assignee:

Seattle Biomedical Research Institute - Seattle WA
Ruprecht-Karls-Universitat Heidelberg - Heidelberg
International Classification:

A61K039/015
US Classification:

424268100
Abstract:

Method for inoculating a vertebrate host against malaria, by administering to the host a live organism that is genetically engineered to disrupt a liver-stage-specific gene function.

Plasmodium Axenic Liver Stages As A Noninfectious Whole Organism Malaria Vaccine
view source
US Patent:

20050233435, Oct 20, 2005
Filed:

Sep 7, 2004
Appl. No.:

10/936786
Inventors:

Stefan Kappe - Seattle WA, US
Victor Nussenzweig - New York NY, US
Karine Kaiser - New York NY, US
Nelly Camargo - Seattle WA, US
Agam Singh - New York NY, US
Assignee:

NYU Medical Center - New York NY
International Classification:

C12N001/10
A61K039/015
US Classification:

435258200
Abstract:

The present invention relates to the treatment and prevention of malaria infection. In particular, the present invention provides novel noninfectious, whole organism vaccines for malaria, which vaccines comprise a axenic liver stage. The invention also provides methods to treat and prevent malaria by administering such axenic liver stage vaccines, as well as methods to generate axenic liver stages.

Live Genetically Engineered Protozoan Vaccine
view source
US Patent:

20060121060, Jun 8, 2006
Filed:

Jun 22, 2005
Appl. No.:

11/165586
Inventors:

Stefan Kappe - Seattle WA, US
Kai-Uwe Matuschewski - Heidelberg, DE
International Classification:

A61K 39/008
A61K 39/005
US Classification:

424269100
Abstract:

The invention provides methods for inducing an immune response in a vertebrate host against a protozoan parasite, comprising administering to the host a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host. Representative protozoan parasites belong to the phyla Apicomplexa and Kinetoplastida. The vertebrate host may be a mammal or a bird.

Live Genetically Attenuated Malaria Vaccine
view source
US Patent:

20070009556, Jan 11, 2007
Filed:

Aug 30, 2006
Appl. No.:

11/513649
Inventors:

Stefan Kappe - Seattle WA, US
Kai-Uwe Matuschewski - Heidelberg, DE
Ann-Kristin Mueller - Dossenheim, DE
Assignee:

Seattle Biomedical Research Institute - Seattle WA
Ruprecht-Karls-Universitat Heidelberg - Heidelberg
International Classification:

A61K 39/015
US Classification:

424272100
Abstract:

Method for inoculating a vertebrate host against malaria, by administering to the host a live organism that is genetically engineered to disrupt a liver-stage-specific gene function.

Live Genetically Attenuated Malaria Vaccine
view source
US Patent:

20080032388, Feb 7, 2008
Filed:

Dec 20, 2004
Appl. No.:

10/583186
Inventors:

Stefan H.I. Kappe - Seattle WA, US
Kai-Uwe C. Matuschewski - Heidelberg, DE
Ann-Kristin Mueller - Dossenheim, DE
Assignee:

Seattle Biomedical Research Institute - Seattle WA
Ruprecht-Karls-Universitat Heidelberg - Heidelberg
International Classification:

C12N 1/10
US Classification:

4352582
Abstract:

Method for inoculating a vertebrate host against malaria, by administering to the host a live organism that is genetically engineered to disrupt a liver-stage-specific gene function.

Plasmodium Liver Stage Antigens
view source
US Patent:

20100166794, Jul 1, 2010
Filed:

Mar 11, 2010
Appl. No.:

12/722439
Inventors:

Patrick Duffy - Seattle WA, US
Stefan H.I. Kappe - Seattle WA, US
Urszula Krzych - Washington DC, US
Lawrence W. Bergman - Landsdale PA, US
Vladislav A. Malkov - Seattle WA, US
Alice Tarun - Shoreline WA, US
Jason W. Wendler - Lincoln NE, US
Igor Bacik - Rockville MD, US
Assignee:

SEATTLE BIOMEDICAL RESEARCH INSTITUTE - Seattle WA
The USA, as Represented by the Secretary of the Army,on Behalf of the Walter Reed - Fort Detrick MD
Philadelphia Health & Education Corporation, d/b/a Drexel University College of Medicine "DUCOM" - Philadelphia PA
International Classification:

A61K 39/002
C07K 14/445
C07H 21/04
A61P 33/06
US Classification:

4241911, 530350, 536 237
Abstract:

The invention provides isolated liver stage polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage polypeptides of the invention, compositions comprising one or more liver stage polypeptides of the invention, methods for inducing an immune response against the liver stage polypeptides, and methods for treating and diagnosing liver stage malaria.

Live Genetically Attenuated Malaria Vaccine
view source
US Patent:

20110033502, Feb 10, 2011
Filed:

May 6, 2008
Appl. No.:

12/116159
Inventors:

Stefan H.I. Kappe - Seattle WA, US
Kai-Uwe C. Matuschewski - Berlin, DE
Ann-Kristin Mueller - Dossenheim, DE
Kelley van Buskirk - Columbia City IN, US
Mehdi Labaied - Bainbridge Island WA, US
Ahmed Sayed Ibrahim Aly - Seattle WA, US
Alan Frederick Cowman - Melbourne, AU
Alexander Gerd Maier - Coburg, AU
International Classification:

A61K 39/015
A61P 33/06
C12N 1/10
US Classification:

4242721, 4352582
Abstract:

Method for inoculating a vertebrate host against malaria, by administering to the host a live organism that is genetically engineered to disrupt a liver-stage-specific gene function.

Doubly Attenuated Late Liver Stage Malaria Parasites And Related Compositions And Methods
view source
US Patent:

20210353731, Nov 18, 2021
Filed:

Feb 1, 2021
Appl. No.:

17/163932
Inventors:

- Seattle WA, US
Stefan H.I. Kappe - Seattle WA, US
Dorender A. Dankwa - Seattle WA, US
Assignee:

SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE - Seattle WA
International Classification:

A61K 39/015
C07K 14/445
C12N 1/36
Abstract:

The disclosure relates to doubly attenuated malaria parasites that have had the functionality of LISP2 and PlasMei2 genes interrupted through genetic manipulation. The double attenuated malaria parasites disclosed herein are useful for methods and compositions for stimulating of vertebrate host immune systems because of the complete cessation of lifecycle progression in the late liver stage, while providing a comprehensive antigenic presentation representing wildtype liver stage parasites. The disclosure also relates to the additional blood stage and gametocyte antigens to compositions of genetically attenuated malaria parasites (GAPs) to enhance efficient immune stimulation and prevention of disease and transmission related to the presence of blood stage parasites.

News

A box of 200 mosquitoes did the vaccinating in this malaria trial. That's not a joke!

view source

"We think we can obviously do better," says Stefan Kappe, an author of the study and parasitologist at University of Washington Seattle and Seattle Children's Research Institute. He and Murphy hope to improve the efficacy of their team's vaccine by putting it into syringes instead of using mosquitoe
Date: Sep 20, 2022
Category: Health
Source: Google

Scientists want to use a genetically modified malaria parasite as a vaccine against the disease

view source

I would say that the main reason why we don't have an effective malaria vaccine is the complexity of the parasitic organism that causes malaria, says Stefan Kappe, director of Translational Science at the Center for Infectious Disease Research in Seattle.
Date: Jan 22, 2017
Category: Health
Source: Google

Genetically Engineered Vaccine Prevents Malaria in Mice, Findings Show

view source

"[Removing] these three genes make sure the parasite cannot develop to the next stage of infection, which occurs in the blood, which causes all of the disease and death associated with malaria," said CIDRs Stefan Kappe, one of the main authors of the study, published Wednesday in the journal Scienc
Date: Jan 04, 2017
Category: Health
Source: Google

Promising malaria vaccine disables key parasite genes

view source

A team led by parasitologist Stefan Kappe at the Center for Infectious Disease Research in Seattle in Washington gave a rodent version of this genetically attenuated parasite, or GAP, to mice and showed that they were completely protected when later infected with an unmodifiedor wild-typeversio
Date: Jan 04, 2017
Category: Health
Source: Google

On the path to a new-generation malaria vaccine

view source

Our approach permanently and uniformly cripples the very complex malaria parasite so that it cannot cause disease and, instead, effectively primes the immune system, CIDRs Dr. Stefan Kappe, one of the papers main authors, said in a statement.
Date: Jan 04, 2017
Category: Health
Source: Google

Incredulity turns to praise as malaria vax posts positive PhI data

view source

community. "The trial results constitute the most important advance in malaria vaccine development since the first demonstration of protection with radiation attenuated sporozoite immunization by mosquito bite in the 70s," Seattle Biomedical Research Institute malaria researcher Stefan Kappe told Nature.
Date: Aug 09, 2013
Source: Google

New malaria vaccine 100% effective

view source

advance in malaria vaccine development since the first demonstration of protection with radiation attenuated sporozoite immunization by mosquito bite in the 70s. This is a pivotal success," said Stefan Kappe, a malaria researcher at the Seattle Biomedical Research Institute in Washington, to Nature.
Date: Aug 08, 2013
Source: Google